Candela

Company Overview

Snapshot

Founded in July 2000, Candela operates with over 500 employees. The company has engaged in 2 funding rounds, attracting 1 investor, Israel HealthCare Ventures. A significant milestone occurred in July 2017 when Candela was acquired by Apax Partners.

Business overview

Candela is an aesthetic device company specializing in advanced solutions for a wide range of medical aesthetic applications. Its comprehensive product portfolio, including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO2RE, CO2RE Intima, Profound, and els Plus, addresses needs such as body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate wellness, and treatments for vascular and pigmented lesions, acne, leg veins, and cellulite. The company serves the health tech and life sciences sector with a global distribution footprint.

Strategic signal

In October 2022, Candela Medical postponed its $250 million IPO. This indicates a strategic re-evaluation of its public market entry amidst potentially challenging market conditions, signaling a shift in its immediate growth and financing strategy for investors.

Company Intelligence Q&A

When was Candela acquired and by whom?

Candela was acquired by Apax Partners in July 2017.

What was a notable event regarding Candela's public offering plans?

In October 2022, Candela Medical postponed its planned $250 million IPO, which was expected to raise $250 million.

Did Candela engage in any acquisitions?

In September 2018, Candela acquired Ellipse, and in November 2015, it acquired Orscan Technologies.

What was a key partnership for Candela in the past?

In November 2013, Candela (then Syneron Medical) joined forces with Unilever for Iluminage Beauty.

What was a significant product approval for Candela?

In June 2020, Candela announced Health Canada approval of two new gynecological indications for its CO2RE laser platform.